Featured Publications
Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial
Sundar R, Kumarakulasinghe N, Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan A, Hoppe M, Jeyasekharan A, Ng C, De Simone M, Grabsch H, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut 2021, 71: 676-685. PMID: 33980610, PMCID: PMC8921574, DOI: 10.1136/gutjnl-2021-324060.Peer-Reviewed Original ResearchConceptsDisease free survivalValidation cohortGastric cancerGene signatureSurvival benefitPac-SensitiveNo survival differenceSelection of patientsGC trialsFree survivalPaclitaxel chemotherapyCurative surgeryMetastatic patientsPredictive biomarkersTraining cohortSurvival differencesIndependent cohortNanoString panelGC patientsPaclitaxelPatientsNanoString profilingCohortGroup trialUFTAre we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
Molassiotis A, Cheng H, Lopez V, Au J, Chan A, Bandla A, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Sundar R. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019, 19: 132. PMID: 30736741, PMCID: PMC6368751, DOI: 10.1186/s12885-019-5302-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesDose-Response Relationship, DrugFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasm StagingNeoplasmsPatient Reported Outcome MeasuresPeripheral Nervous System DiseasesPrevalenceProspective StudiesQuality of LifeSeverity of Illness IndexConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNeurotoxic chemotherapyPrevalence of sensory neuropathyCohort study of patientsCumulative chemotherapy dosePlatinum-based chemotherapyLongitudinal cohort study of patientsMeasuring chemotherapy-induced peripheral neuropathyStudy of patientsNerve conduction studiesAssessment of chemotherapy-induced peripheral neuropathyCIPN incidencePatient-reported outcome measuresAssociated with onsetLongitudinal cohort studyChemotherapy doseMotor neurotoxicityClinician-based scalesMotor neuropathySensory neuropathyChemotherapyNeuropathyNatural historyPatients
2024
Pushing the Frontiers of Cancer Research: Highlights from the Frontiers in Cancer Science Conference 2023.
Lee Y, Chen L, Chew V, Chow E, Deng L, Hunziker W, Lee A, Leong G, Ngeow J, Pervaiz S, Sabapathy K, Skanderup A, Sundar R, Tay Y, Virshup D, Wong S, Tergaonkar V, Tam W. Pushing the Frontiers of Cancer Research: Highlights from the Frontiers in Cancer Science Conference 2023. Cancer Research 2024, 84: 1195-1198. PMID: 38616656, DOI: 10.1158/0008-5472.can-24-0721.Commentaries, Editorials and LettersFRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study)
Ling R, Ueno R, Alamgeer M, Sundararajan K, Sundar R, Bailey M, Pilcher D, Subramaniam A. FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study). British Journal Of Anaesthesia 2024, 132: 695-706. PMID: 38378383, DOI: 10.1016/j.bja.2024.01.020.Peer-Reviewed Original ResearchConceptsElective surgeryCohort studyMulticentre retrospective cohort studyRetrospective multicentre cohort studyPatients admitted to intensive care unitsAssociated with poor outcomesAssociated with similar effectsAssociated with lower survivalCancer-related surgeryMulticentre cohort studyRetrospective cohort studyLong-term outcomesIntensive care unitAssociated with mortalityPoor outcomeFollow-upICU admissionPrimary outcomeCare unitSurgeryPatientsSurvival informationCancerFrailtyICU
2023
82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Choo J, Jeraj S, Chan G, Sundar R, Yong W, Lee M, Ngoi N, Wong A, Soo R, Chee C, Lim J, Goh B, Lee S, Tan D. 82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies. Annals Of Oncology 2023, 34: s1498. DOI: 10.1016/j.annonc.2023.10.217.Peer-Reviewed Original ResearchPhase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines
Lim J, Ow S, Wong A, Lee M, Chan G, Low J, Sundar R, Choo J, Chong W, Ang Y, Tai B, Lee S. Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines. European Journal Of Cancer 2023, 193: 113311. PMID: 37717281, DOI: 10.1016/j.ejca.2023.113311.Peer-Reviewed Original ResearchMetastatic breast cancerObjective response rateProgression-free survivalPhase II studyCohort ABreast cancerDetermination of progression-free survivalSingle-arm phase II studyTreatment of metastatic breast cancerConsistent with known toxicitiesMedian progression-free survivalClinical benefit rateDose-confirmation phaseTreated with FTD/TPIDose modificationII studyCohort BBenefit rateFTD/TPISafety profileFluoropyrimidineGastric cancerPatientsResponse rateAntitumour activityEvidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply
Zhao J, Pietrantonio F, Sundar R. Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply. JAMA Oncology 2023, 9: 1005-1006. PMID: 37166787, DOI: 10.1001/jamaoncol.2023.0975.Commentaries, Editorials and LettersClinical efficacy and Long-term Immunogenicity of early triple dose COVID-19 mRNA vaccine in cancer patients
Li J, Lee M, Peng S, Bin Lee A, Tay R, Chee C, Ho C, Walsh J, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and Long-term Immunogenicity of early triple dose COVID-19 mRNA vaccine in cancer patients. European Journal Of Surgical Oncology 2023, 49: e60-e61. PMCID: PMC9941290, DOI: 10.1016/j.ejso.2022.11.202.Peer-Reviewed Original ResearchClinical outcome and prognostic factors for Asian patients in Phase I clinical trials
Loh J, Wu J, Chieng J, Chan A, Yong W, Sundar R, Lee S, Wong A, Lim J, Tan D, Soo R, Goh B, Tai B, Chee C. Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials. British Journal Of Cancer 2023, 128: 1514-1520. PMID: 36797357, PMCID: PMC10070409, DOI: 10.1038/s41416-023-02193-2.Peer-Reviewed Original ResearchConceptsNeutrophil-lymphocyte ratioRoyal Marsden HospitalPhase I studyPhase I clinical trialPoor ECOG statusPre-treated patientsPrimary tumor sitePhase I populationLonger-term survivalECOG statusPrognostic factorsPrognostic scoreRetrospective reviewTumor siteAsian patientsSolid tumorsClinical outcomesPoor prognosisBackgroundPatient selectionPrognostic abilityPrognostic modelPatientsPrognosisIncreased scoresScoresImmune checkpoint inhibitor combinations—current and emerging strategies
Walsh R, Sundar R, Lim J. Immune checkpoint inhibitor combinations—current and emerging strategies. British Journal Of Cancer 2023, 128: 1415-1417. PMID: 36747017, PMCID: PMC10070427, DOI: 10.1038/s41416-023-02181-6.Commentaries, Editorials and Letters
2022
Resistance to systemic immune checkpoint inhibition in the peritoneal niche
Chia D, Gwee Y, Sundar R. Resistance to systemic immune checkpoint inhibition in the peritoneal niche. Journal For ImmunoTherapy Of Cancer 2022, 10: e004749. PMID: 35728873, PMCID: PMC9214396, DOI: 10.1136/jitc-2022-004749.Commentaries, Editorials and LettersConceptsImmune checkpoint inhibitionResistance to immune checkpoint inhibitionPeritoneal metastasisCheckpoint inhibitionMetastatic nicheResponse to ICIImmune checkpoint inhibition therapySensitive to immune checkpoint inhibitionIntrinsic tumor factorsPresence of ascitesDeficient mismatch repairPeritoneal microenvironmentTumor factorsMalignant ascitesPrimary resistanceClinical entityTherapeutic optionsMicrosatellite instable tumorsPeritoneal cavityGastrointestinal cancerParacrine factorsAscitesConcurrent ascitesPatientsInstable tumorsKMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves
Zhao J, Syn N, Tan B, Yap D, Teo C, Chan Y, Sundar R. KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves. BMC Medical Research Methodology 2022, 22: 93. PMID: 35369867, PMCID: PMC8978435, DOI: 10.1186/s12874-022-01567-z.Peer-Reviewed Original ResearchConceptsMonte Carlo simulationsLimits of errorSubgroup survival dataCarlo simulationsSurvival dataKaplan-MeierKaplan-Meier survival curvesExtensive Monte Carlo simulationsOriginal survival dataFollow-up timeCox proportional hazards modelsSubgroups of clinical interestPublished Kaplan-Meier survival curvesMarginal Cox proportional hazards modelsProportional hazards modelMatched patientsSecondary data analysisSystematic errorsSurvival curvesProportion of missing dataHazards modelClinical interestPatientsPrimary manuscriptsKM plotsUNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies
Tan D, Lim W, Yong J, Ng C, Muthiah M, Tan E, Xiao J, Lim S, Pin Tang A, Pan X, Kabir T, Bonney G, Sundar R, Syn N, Kim B, Dan Y, Noureddin M, Loomba R, Huang D. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. Clinical Gastroenterology And Hepatology 2022, 21: 1475-1484. PMID: 35181565, DOI: 10.1016/j.cgh.2022.02.018.Peer-Reviewed Original ResearchConceptsUNOS-DS criteriaHepatocellular carcinoma recurrenceUNOS-DSDown-stagingOverall survivalLiver transplantationHepatocellular carcinomaMilan criteriaPost-LTLiver transplantation of hepatocellular carcinomaTransplantation of hepatocellular carcinomaAbstractText Label="RESULTS">WeAdult HCC patientsBaseline tumor burdenPost-LT outcomesDown-staging treatmentTumor burdenHCC patientsEmbase databasesPooled analysisPatientsIndividual participant dataRecurrenceClinical validationMeta-analysis
2021
Small bowel adenocarcinoma in Crohn’s disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes
Chin Y, Jain S, Lee M, Ng C, Lin S, Mai A, Muthiah M, Foo F, Sundar R, Ong D, Leow W, Leong R, Chan W. Small bowel adenocarcinoma in Crohn’s disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. International Journal Of Colorectal Disease 2021, 37: 239-250. PMID: 34704127, DOI: 10.1007/s00384-021-04050-1.Peer-Reviewed Original ResearchConceptsMolecular analysis findingsCrohn's diseaseOverall survivalClinical presentationBowel adenocarcinomaCD patientsInflammatory bowel disease patientsMeta-analysisSmall bowel adenocarcinomaAssociated with Crohn's diseaseConclusionOur meta-analysisMethodsElectronic databases MedlineStatistically significant increaseEpithelial dysplasiaAbdominal painMismatch repair deficiencyKRAS mutationsRadiological featuresHistopathological findingsGenetic mutationsPatientsRepair deficiencyResultsIn totalDisease patientsHistopathology
2020
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Sundar R, Smyth E, Peng S, Yeong J, Tan P. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Frontiers In Oncology 2020, 10: 763. PMID: 32500029, PMCID: PMC7243739, DOI: 10.3389/fonc.2020.00763.Peer-Reviewed Educational MaterialsImmune checkpoint inhibitionGastroesophageal cancerPredictive biomarkersCheckpoint inhibitionRandomized phase III studyImmune checkpoint inhibitor trialsValidation of predictive biomarkersCheckpoint inhibitor trialsPhase III studySubgroup of patientsIII studiesSurvival benefitInhibitor trialsPatient selectionGastroesophagealNovel biomarkersPrecision oncologyCancer treatmentCancerRegulatory approvalImmunotherapyNegative resultsBiomarkersPatientsInhibition
2019
Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials.
Scaranti M, Sundar R, Daly R, Collins D, Dolling D, Gennatas S, Rao Baikady B, Kaye S, Banerji U, Lopez J, De Bono J, Minchom A. Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials. Journal Of Clinical Oncology 2019, 37: e18175-e18175. DOI: 10.1200/jco.2019.37.15_suppl.e18175.Peer-Reviewed Original ResearchPhase I trialI trialMean step countPhase I clinical trialPatient's physical functionHeart ratePredicting patient survivalDrug Development UnitStep countsECOG PSPhysical functionPatient survivalElectronic activity monitorsMedical oncologistsRecord heart ratePatient groupPhysician biasTreatment cyclesTreatment decisionsPatientsActivity monitoringPatient outcomesStatistical significanceOSPhysicians
2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial
Yong W, Rha S, Tan I, Choo S, Syn N, Koh V, Tan S, Asuncion B, Sundar R, So J, Shabbir A, Tan C, Kim H, Jung M, Chung H, Ng M, Tai D, Lee M, Wu J, Yeoh K, Tan P, Consortium O. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial. Clinical Cancer Research 2018, 24: 5272-5281. PMID: 30045931, DOI: 10.1158/1078-0432.ccr-18-0193.Peer-Reviewed Original ResearchConceptsGenomic classifierManagement of advanced gastric cancerGastric cancerS-1 regimenOpen-label phaseAdvanced gastric cancerGastric cancer chemotherapySensitivity to oxaliplatinTreated with cisplatinTumor gene expressionMedian turnaround timeTreated with SPGene expression signaturesSOX chemotherapyPatient tumorsTreatment stratificationStratify patientsMetabolic signaturesChemotherapyGene expression profilesOxaliplatinPatientsCancer chemotherapyPredictive valueResponse rate
2017
Genomic predictors of neoadjuvant chemotherapy (NACT) response in breast cancer (BC).
Wong A, Tan K, Sundar R, Ow S, Pang A, Yap H, Chan C, Hartman M, Iau P, Buhari S, Mogro M, Tan I, Wang L, Yang H, Goh B, Lee S. Genomic predictors of neoadjuvant chemotherapy (NACT) response in breast cancer (BC). Journal Of Clinical Oncology 2017, 35: e12122-e12122. DOI: 10.1200/jco.2017.35.15_suppl.e12122.Peer-Reviewed Original ResearchVariant allele frequencyNeoadjuvant chemotherapyPost-NACTPoor outcomeBC patientsBreast cancerPredictors of neoadjuvant chemotherapyEffect of neoadjuvant chemotherapyEmergent mutationsMean tumor sizePost-NACT tumorsSomatic single nucleotide variantsDiagnosed BC patientsSingle nucleotide variantsWhole-exome sequencingMatched normal DNABC relapseNOTCH2 mutationsTumor sizeClinical outcomesNucleotide variantsLesion reductionExome sequencingPatientsMutational landscapeProspective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients.
Walsh R, Lee S, Seng K, Wang L, Ho G, Ow S, Kumarakulasinghe N, Sundar R, Lee X, Yap H, Jeyasekharan A, Pang A, Ho J, Tan C, Lim Y, Malik R, Wan Ishak W, Goh B, Tai B, Wong A. Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients. Journal Of Clinical Oncology 2017, 35: 1056-1056. DOI: 10.1200/jco.2017.35.15_suppl.1056.Peer-Reviewed Original ResearchClinical benefit rateMetastatic breast cancerHormone receptorsMetastatic breast cancer patientsUDP-glucuronosyltransferaseClinical treatment efficacyGlucuronidation in vitroUGT2B17 genotypeBenefit rateClinical benefitProspective studyBreast cancerActive metabolitePK dataPD biomarkersTreatment efficacyPatientsPharmacodynamicsPD effectsResponse rateUGT2B17C maxActivity indexPharmacokineticsSignificant PDFirst-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.
Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Kondo S, Shimomura A, Fujiwara Y, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Huang J, Nishio M, Yamamoto N. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors. Journal Of Clinical Oncology 2017, 35: 2546-2546. DOI: 10.1200/jco.2017.35.15_suppl.2546.Peer-Reviewed Original ResearchTAS-116Solid tumorsFirst-in-human phase I studyAntitumor activityOral HSP90 inhibitorAccelerated titration designPhase 2 studyPhase I studyPreliminary antitumor activityPhase 1 studyEvidence of target engagementDose expansionFlat doseEscalating dosesDose proportionalityRepeated administrationQD scheduleSafety profileEye disordersIncreased creatinineAdverse eventsTitration designDays administrationNon-purinePatients